Authors: Price LH, et al.
Title: Ziprasidone in adjunctive treatment of acute bipolar mania: randomized, double blind, placebo-controlled trial.
Reference: 42nd ACNP annual meeting 2003. [Congress abstract]
Purpose: To evaluate the efficacy and tolerability of ziprasidone versus placebo in patients with bipolar mania who were receiving concomitant lithium.
Study design: Randomized, double-blinded, placebo-controlled trial.
Follow up: 3 weeks.
Patients: 205 patients (102 ziprasidone, 103 placebo).
Treatment: Ziprasidone 80–160 mg/day.
Results: At day 4, rates of change were significantly greater in patients treated with ziprasidone compared with placebo, but at day 14, rates of change were comparable in the two treatment groups. Ziprasidone and lithium in combination was generally tolerated.